Abstract: This briefing is about strengthening the evidence base for and considering barriers to psychedelic assisted therapies. It underlines the importance of addressing psychedelic treatment costs, determining where and how psychedelic treatment is made available to veterans, and ensuring that veterans who receive this treatment do so safely. This testimony was presented before the House Committee on Veterans Affairs, Subcommittee on Health on November 14, 2023.